Home » News » OnenessPoint Company » Emerging companies in the field of synthetic biology

Emerging companies in the field of synthetic biology

Views: 0     Author: Site Editor     Publish Time: 2022-09-08      Origin: Site

According to CB Insights, synthetic biology startups will raise $18 billion globally in 2021, which is nearly as much as all the investments received in the previous 12 years (2009-2020) in one year, and this year, the investment wave could reach a new high.

So far in 2022, more than 20 domestic synthetic biology companies have announced funding rounds.

The synthetic biology market is booming, driven by both the supply and demand sides. On the supply side, traditional production methods have difficulty in meeting new market demands; on the demand side, industries are in urgent need of new molecules and new production methods. On the other hand, it is also driven by national policies.

In China, the establishment of the "Double Carbon" target and the release of the "14th Five-Year Plan" for the development of bio-economy have elevated biomanufacturing to the status of a national strategic emerging industry, and at the same time, a large number of young talents have been able to grow rapidly and a number of high-quality synthetic biology startups have been incubated based on the scientific and technological platforms laid out and built in the field of synthetic biology in China.

In 2021, Andy Zhuang, who has rich experience in entrepreneurship in the field of biogenetics, joined hands with Shubo Shi, a professor of synthetic biology at the High Precision Innovation Center of Beijing University of Chemical Technology, and several other core personnel from well-known synthetic biology research institutions and enterprises such as Institute of Microbiology, Chinese Academy of Sciences and Bluepha as co-founders to establish Nanjing OnenessPoint Health Technology Co., Ltd. (hereinafter referred to as " OnenessPoint ").

The team was then also recognized and joined as in-depth R&D consultants by several industry experts. It is understood that the existing core team of OnenessPoint shows a trend of specialization, efficiency, versatility and more youthfulness. The team of R&D advisors includes experts from the 10,000 people program in the field of microbiology and emerging young people in the field of structural biology and artificial intelligence.

The industrialization team is also composed of senior personnel with more than 10 years of experience in fermentation and purification from large fermentation companies such as Meihua group; the technical R&D team includes a number of PhDs and masters from famous universities in China such as University of Chemical Technology Beijing, University of Science and Technology of China, University of Science and Technology of Tianjin and other research laboratories.



In the same year, OnenessPoint completed an angel round of financing of tens of millions of RMB invested by Enran Ventures, and has achieved rapid development and abundant results in the past six months. At present, OnenessPoint has completed the construction of three technology platforms with unique non-model bio-automation transformation technology as the core, and expanded several cosmetic and innovative food ingredients pipelines, including anti-aging cosmetic ingredients and other product pipelines have reached mass production level, and are cooperating with many cosmetic brands and ODMs.

Andy Zhuang, the founder and CEO of OnenessPoint, graduated from Delft University of Technology in the Netherlands, one of the top universities in Europe, and has held senior management positions in Lenovo, Jingdong and other Fortune 500 companies. He then entered the biomedical field for self-employment, combining his professional background in data modeling, and chose to start his own business in the field of genetic data.

As an entrepreneur and senior researcher in the genetic industry, Andy Zhuang believes that "the current development of synthetic biology means that the time has come when human beings can efficiently integrate and utilize the source code of nature, which is a point worth remembering in the whole history of mankind. With this ability, we should make good use of nature's source code, lead the development of science and technology back to the basics, and contribute to the creation of a green and sustainable future."

Shuobo Shi is the co-founder and Vice President of Research and Development of OnenessPoint, responsible for leading the R&D team and product pipeline. After graduating from Tianjin University in 2009, he joined Chalmers University of Technology and studied under Prof. Jens Nielsen (Foreign Member of Chinese Academy of Engineering, Member of Nobel Prize Review Committee, Founding President of International Society for Metabolic Engineering, Foreign Member of both U.S. Academies) in the field of synthetic biology. In 2013, he joined Prof. Huimin Zhao's lab at the University of Illinois at Urbana-Champaign in Singapore, working on the development of the underlying tools for synthetic biology.

After returning to China, Shubo Shi established an independent lab at Beijing University of Chemical Technology to conduct basic and applied research in metabolic engineering and synthetic biology, constructing and modifying microorganisms to enable their direct use for efficient production of chemicals, plant natural products and other biological products, and developing and optimizing CRISPR genome editing tools for strain improvement and other applications.

If you have any questions, please contact us via email or telephone and we will get back to you as soon as possible.


Quick Links

Contact Us

Copyright© 2022 OnenessPoint. | Sitemap